Aleix Prat: Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer
Aleix Prat, Head of the Medical Oncology Department at Hospital Clínic Barcelona, shared a post on X about a recent paper by Fara Brasó-Maristany et al. titled “Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer” published in Scientific Reports, commenting: .
“What a week! here our 3rd article published by our lab Scientific Reports!
Led by Dr. Fara Brasó-Maristany and pre-doc Natàlia Lorman-Carbó.
Using preclinical models and mining gene expression data from breast tumors, we observed that both CDK4/6 inhibitors effectively modulate key biological pathways in HR+/HER2- breast cancer.
However, nuances in their impact, particularly on the HER2-enriched signature, are dose-dependent, and warrant further investigation.
SOLTI HARMONIA trial (NCT05207709) ongoing to test this hypothesis!”
Authors: Natàlia Lorman-Carbó, Olga Martínez-Sáez, Aranzazu Fernandez-Martinez, Patricia Galván, Nuria Chic, Isabel Garcia-Fructuoso, Adela Rodríguez, Raquel Gómez-Bravo, Francesco Schettini, Paula Blasco, Oleguer Castillo, Blanca González-Farré, Barbara Adamo, Maria Vidal, Montserrat Muñoz, Charles M. Perou, Marcos Malumbres, Joaquín Gavilá, Tomás Pascual, Aleix Prat and Fara Brasó-Maristany.
Source: Aleix Prat/X